Physician profile
Jiten D Patel
NPI 1689895211
$200,157.02
in general payments reported to CMS, 2019-2025
38 companies · $34K in 2025
The $34K reported for 2025 was more than what 97% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62K · 2020: $13K · 2021: $18K · 2022: $18K · 2023: $14K · 2024: $40K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $58K · Travel and Lodging: $14K · Food and Beverage: $7,484 · Consulting Fee: $6,550 · Education: $2,959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $58,002.00 |
| Travel and Lodging | $13,810.46 |
| Food and Beverage | $7,484.13 |
| Consulting Fee | $6,550.00 |
| Education | $2,958.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $125,780.87 | 2019-2025 | Ofev, Stiolto Respimat, Jascayd |
| Actelion Pharmaceuticals US, INC. | $48,618.47 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| United Therapeutics Corporation | $9,191.37 | 2019-2025 | Tyvaso, Remodulin, Tyvaso |
| Intuitive Surgical, INC. | $6,392.02 | 2022-2024 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $1,806.66 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $1,481.96 | 2019-2025 | Trelegy Ellipta, Nucala |
| Steris Corporation | $1,437.77 | 2025 | |
| Pulmonx Corporation | $1,313.30 | 2019-2023 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Electromed, INC. | $694.20 | 2022-2025 | Smartvest |
| Grifols USA, LLC | $324.92 | 2019-2025 | Prolastin-C Liquid |
| Boston Scientific Corporation | $271.75 | 2022-2024 | Exalt Model D, Acquire |
| Regeneron Healthcare Solutions, INC. | $258.22 | 2020-2025 | Dupixent |
| Insmed, INC. | $250.02 | 2021-2025 | Arikayce |
| Genzyme Corporation | $243.31 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $196.75 | 2023-2025 | Winrevair |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $185.69 | 2021-2024 | |
| Mylan Specialty L.P. | $183.26 | 2019-2024 | Yupelri |
| Baxter Healthcare | $174.85 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Genentech USA, INC. | $172.72 | 2019-2024 | Xolair |
| Galvanize Therapeutics, INC | $145.00 | 2023 | Aliya System |
| Takeda Pharmaceuticals U.S.A., INC. | $134.26 | 2024-2025 | Glassia |
| Philips North America LLC | $126.07 | 2022-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Amgen INC. | $123.95 | 2021-2025 | Tezspire, Tavneos |
| Ethicon INC. | $121.53 | 2022 | |
| Advanced Respiratory, INC | $116.09 | 2019-2021 | |
| Verona Pharma, INC. | $86.69 | 2025 | Ohtuvayre |
| Pinnacle Biologics, INC | $84.78 | 2019-2025 | Photofrin |
| Pfizer INC. | $61.68 | 2023 | |
| Gilead Sciences, INC. | $41.22 | 2019 | |
| Novartis Pharmaceuticals Corporation | $32.81 | 2023 | |
| Sunovion Pharmaceuticals INC. | $26.51 | 2019 | |
| Covidien LP | $18.23 | 2020 | |
| Viatris Specialty LLC | $18.18 | 2025 | Yupelri |
| Astellas Pharma US INC | $17.92 | 2019 | |
| Medtronic, INC. | $12.07 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.92 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jiten Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.